• Name

  (+-)metoprolol-(+)tartrate

• EINECS 260-148-9
• CAS No. 56392-17-7
• Article Data4
• CAS DataBase
• Density 1.1946 (rough estimate)
• Solubility Soluble in water (>1000 mg/ml), methanol (>500 mg/ml), chloroform (496 mg/ml), ethanol (31 mg/ml at 25°C), and DMSO (100 mg/ml at 25°C).
• Melting Point 120oC
• Formula 2(C₁₅H₂₅NO₃)^.(C₄H₆O₆)
• Boiling Point 398.6 °C at 760 mmHg
• Molecular Weight 684.825
• Flash Point 194.9 °C
• Transport Information
• Appearance crystalline powder
• Safety 7-16-36/37-45-24/25
• Risk Codes 11-23/24/25-39/23/24/25
• Molecular Structure
• Hazard Symbols F,T
• Synonyms Metoprolol-(+,-) (+)-tartrate salt;2-Propanol,1-[4-(2-methoxyethyl)phenoxy]-3- [(1-methylethyl)amino]-,(2R,3R)-2,3- dihydroxybutanedioate (2:1) (salt);Betaloc;Beloc;Seloken;Lopressor;Metoprolol tartrate (JAN/USP);Lopresor;(2R,3R)-2,3-dihydroxybutanedioic acid; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;Prestwick_1009;2,3-dihydroxybutanedioic acid; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;Lopressor (TN);Metoprolol tartaric acid;
• PSA 216.50000
• LogP 1.88560

Metoprolol tartrate Specification

1. Introduction of Metoprolol tartrate
Metoprolol tartrate is also named as 2-Propanol, 1-(isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-, (+-)-, tartrate (2:1). With the classification codes of Anti-adrenergic [beta-receptor]; Drug/Therapeutic Agent; Human Data; Reproductive Effect, its product categories are Cardiovascular; Amines; Aromatics; Intermediates & Fine Chemicals; Pharmaceuticals; Adrenoceptor. Additionally, keep this chemical in the cool and dry place where the room is ventilated.

2. Properties of Metoprolol tartrate
Other characteristics of the Metoprolol tartrate can be summarised as followings: (1)ACD/LogP: 1.79; (2)# of Rule of 5 Violations: 0; (3)#H bond acceptors: 4; (4)#H bond donors: 2; (5)#Freely Rotating Bonds: 10; (6)Polar Surface Area: 30.93 Å²; (7)Flash Point: 194.9 °C; (8)Enthalpy of Vaporization: 68.47 kJ/mol; (9)Boiling Point: 398.6 °C at 760 mmHg; (10)Vapour Pressure: 4.52E-07 mmHg at 25°C.

3. Structure Descriptors of Metoprolol tartrate
1) SMILES: O=C(O)[C@H](O)[C@@H](O)C(=O)O.O(c1ccc(cc1)CCOC)CC(O)CNC(C)C.O(C)CCc1ccc(OCC(O)CNC(C)C)cc1
2) InChI: InChI=1/2C15H25NO3.C4H6O6/c2*1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3;5-1(3(7)8)2(6)4(9)10/h2*4-7,12,14,16-17H,8-11H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1
3) InChIKey:YGULWPYYGQCFMP-CEAXSRTFBA

4. Toxicity of Metoprolol tartrate

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	oral	1090mg/kg (1090mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 297, 1983.
human	TDLo	oral	160mg/kg (160mg/kg)	CARDIAC: PULSE RATE VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION LUNGS, THORAX, OR RESPIRATION: CYANOSIS	British Medical Journal. Vol. 1, Pg. 222, 1976.
mouse	LD50	intraperitoneal	202mg/kg (202mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 2439, 1982.
mouse	LD50	intravenous	84mg/kg (84mg/kg)		Drugs in Japan Vol. -, Pg. 614, 1995.
mouse	LD50	oral	1500mg/kg (1500mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Kiso to Rinsho. Clinical Report. Vol. 13, Pg. 2839, 1979.
mouse	LD50	subcutaneous	510mg/kg (510mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Kiso to Rinsho. Clinical Report. Vol. 13, Pg. 2839, 1979.
rabbit	LD50	intravenous	28700ug/kg (28.7mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 297, 1983.
rabbit	LD50	oral	604mg/kg (604mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 297, 1983.
rat	LD50	intraperitoneal	219mg/kg (219mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 2439, 1982.
rat	LD50	intravenous	90mg/kg (90mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION	Kiso to Rinsho. Clinical Report. Vol. 13, Pg. 2839, 1979.
rat	LD50	oral	5500mg/kg (5500mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Kiso to Rinsho. Clinical Report. Vol. 13, Pg. 2839, 1979.
rat	LD50	subcutaneous	1150mg/kg (1150mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Kiso to Rinsho. Clinical Report. Vol. 13, Pg. 2839, 1979.

5. Preparation of Metoprolol tartrate
The 4-(2-methoxyethyl) phenol reacts with Chloro-propylene oxide, and its product reacts with isopropylamine in the existence of isopropanol. Finally the Metoprolol tartrate is obtained when heated at about 100 °C.


6. Use of Metoprolol tartrate
The Metoprolol tartrate, incompatible with strong oxidizing agents, is used in the treatment of a variety of cardiovascular disorder. It's a selective adrenergic beta-1-blocking agent with no stimulatory action. It's binding to plasma albumin is weaker than alprenolol and it may be useful in angina pectoris, hypertension, or cardiac arrhythmias.